https://www.taxtmi.com/news?id=68338 Sigachi Industries advanced a cystic fibrosis API combination (Vanzacaftor, Tezacaftor, Deutivacaftor) involving complex multi-step synthesis and is seeking strategic collaborations for R&D and commercial supply; subject to partnerships and market progression, the company projects ~Rs. 250 crore annual revenue commencing Q4 FY2026-27 and cites innovator patent protection for Vanzacaftor through 2039 as supporting collaboration-led commercial opportunity. en-us Fri, 23 Jan 2026 13:01:03 +0530 Fri, 23 Jan 2026 13:01:03 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=68338 Sigachi Industries advanced a cystic fibrosis API combination (Vanzacaftor, Tezacaftor, Deutivacaftor) involving complex multi-step synthesis and is seeking strategic collaborations for R&D and commercial supply; subject to partnerships and market progression, the company projects ~Rs. 250 crore annual revenue commencing Q4 FY2026-27 and cites innovator patent protection for Vanzacaftor through 2039 as supporting collaboration-led commercial opportunity. News - Fri, 23 Jan 2026 13:01:03 +0530 https://www.taxtmi.com/news?id=68338